Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor

Authors

  • Bahar Ataeinia Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  • Christina Loberg Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany
  • Hanna Kravets Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany
  • Mohsen Beheshti Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany
  • Dirk von Mallek Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany
  • Felix M. Mottaghy Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
  • Alexander Heinzel Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. E-mail: aheinzel@ukaachen.de, Tel: (0049)241 80-88742, Fax: (0049)241 80-82520

DOI:

https://doi.org/10.17179/excli2019-1220

Keywords:

neuroendocrine tumors, metastasis, PRRT, 177Lu-DOTATOC

Abstract

We present the case of a 77 year old male patient with metastatic pancreatic neuroendocrine tumor (NET). The patient was initially treated by extensive surgical resection that however, led to severe complications with delayed recovery. During follow-up, a number of new liver metastases were detected, one of which was in segment I with impending compression of the inferior vena cava. Due to age and general condition of the patient, instead of further surgical treatment, the patient received four cycles of 177Lu-DOTATOC resulting in an overall partial response with successful tumor reduction in liver segment I, resolving an impending compression of vena cava.

Downloads

Published

2019-05-21

How to Cite

Ataeinia, B., Loberg, C., Kravets, H., Beheshti, M., von Mallek, D., Mottaghy, F. M., & Heinzel, A. (2019). Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor. EXCLI Journal, 18, 273–276. https://doi.org/10.17179/excli2019-1220

Issue

Vol. 18 (2019)

Section

Case reports

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).